Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory LymphomaJennifer R. Brown, Farrukh T. Awan, Jason Jiang et al.|Clinical Cancer Research|2015Cited by 55